IGH/BCL2 gene fusion and BCL2 amplification in oral follicular lymphomas
A pilot-study of a minimally invasive technique to elevate the sinus floor membrane and place graft for augmentation using high hydraulic pressure: 18-month follow-up of 20 cases

Philip Jesch, DMD,a Emanuel Bruckmoser, MD, DMD,b Andreas Bayerle, MSc, MBA,c Klaus Eder, MD,d Michaela Bayerle-Eder, MD, PhD,e and Franz Watzinger, MD, DMD,f
Dental Clinic Wienerberg City, Vienna, Austria; Morriston Hospital, Wales, UK; Jeder GmbH, Dental Technology, Vienna, Austria; Private Practice for General Dentistry and Implantology, Vienna, Austria; Medical University of Vienna, Vienna, Austria; and St. Poelten General Hospital, Austria

Objective. To evaluate medical efficacy and safety of crestal, minimally invasive sinus floor augmentation (MISFA) using an innovative method based on high hydraulic pressure.

Study design. Twenty MISFA using the novel Jeder-System were performed in 18 patients at 2 study sites in Vienna, Austria. The Jeder-System consists of the Jeder-drill, the Jeder-pump, and a connecting tube-set. The pump generates high hydraulic pressure (1.5 bar) pushing back the sinus membrane from the drill at the first perforation. The pump also monitors the whole procedure by constantly measuring pressure and volume.

Results. Five percent membrane perforation rate (1/20) only detected in the postoperative computed tomography scan and without implication for implant placement. Height gain of 9.2 ± 1.7 mm achieved (from 4.6 ± 1.4 mm to 13.8 ± 2.3 mm). Average patient satisfaction was 9.82 on scale from 1 to 10 (10 = very satisfied). Mean duration of sick leave was 0.19 days. 18-month survival rate was 95% (1/20 implant lost).

Conclusions. Within the limits of a prospective open cohort study with 20 cases, our data demonstrate the safety and medical efficacy of the novel method. (Oral Surg Oral Med Oral Pathol Oral Radiol 2013;116:293-300)

Although the lateral window technique using a modified Caldwell-Luc approach still represents the standard procedure for sinus floor augmentation in the posterior maxilla region, patients frequently suffer from considerable postoperative pain and swelling.

Therefore, substantial efforts have been made to develop less invasive techniques in order to reduce patient discomfort. As a first improvement of that kind a transalveolar technique with subsequent implantation was introduced by Tatum1 and further developed as an osteotome technique by Summers.2 The controlled primary entry of the drill into the maxillary sinus and the safe elevation of the Schneiderian membrane without perforation are the major challenges of this method. The shortcomings of the Summers technique have motivated the development of a great variety of new methods over the past 15 years. Recent publications on these modifications cover the use of balloons3-5 and hydraulic pressure in humans,6 the appliance of a hydraulic sinus condensing technique,7 a gel-pressure technique,8,9 as well as the use of “intelligent” drills.10,11

In a systematic review of 10 transcrestal sinus lift studies, Tan12 identified a reported membrane perforation rate of 0%-21.4% (mean 3.8%). However, in a parallel review of 33 clinical studies using the lateral approach, Pjetursson13 reported a perforation rate of 0%-58.3% (mean 19.5%). Based on this, Watzek14 rightly doubts the validity of the numbers reported by Tan. As the lateral window technique is done with visual control, it seems unlikely that the perforation rate should be much lower for “blind” procedures in which there is no more than the surgeon’s tactile perception to go by. Rather, we agree with Watzek14 and Rosen15 that using the transcrestal approach clinically insignificant perforations are generally not detected. Therefore,
one can assume that the actual transcrestal perforation rates are much higher than those reported by Tan.

In his review, Tan also identified a reported mean implant success rate of 92.8% for transcrestal sinus elevations. However, Tan confirmed the finding of Rosen16 that the implant failure rate increased with and was correlated to reduced residual bone height.

It was therefore the aim of the present study to evaluate the safety and medical efficacy — in particular in terms of membrane perforation rate and 18-month survival rate — of the novel technique for minimally invasive sinus floor augmentation (MISFA) using the Jeder-System (Jeder GmbH, Vienna, Austria).

MATERIALS AND METHODS

Patient selection

Recruitment and selection of patients took place at the 2 study sites in Vienna, Austria, where the surgical procedures were to be performed. All subjects gave written informed consent to the protocol, which was in compliance with the Helsinki Declaration and had been approved by the Ethics Committee of the City of Vienna, Austria. Study monitor was the Coordination Center for Clinical Studies of the Medical University of Vienna.

Inclusion criteria were as follows: women and men aged 18 years or older, 1 or more missing upper first or second premolars or upper first or second molars, and bone atrophy in the posterior maxilla region resulting in a residual alveolar ridge height of <8 mm.

Exclusion criteria were as follows: residual alveolar ridge height of <3 mm impeding implantation directly after augmentation, Underwood septa localized in intended implant position, sinus membrane thickness >5 mm, maxillary sinusitis or polyposis, pregnant or breastfeeding women, poor oral hygiene, tobacco consumption of more than 15 cigarettes per day, hypercortisolism, corticoid treatment, osteoporosis with intravenous bisphosphonate therapy, subjects suffering from severe chronic diseases as well as immune-suppressed patients.

Pre-operative evaluation

A questionnaire, a clinical examination, a panoramic radiograph and a dental computed tomography (CT) scan were performed to assess inclusion and exclusion criteria. Women of reproductive age had to submit a negative pregnancy test before every CT scan. In case of a positive test result the CT scan would not be performed and the subject would not be included in the study.

Study population

From September 2010 through February 2011, a total number of 18 consecutive patients were recruited and selected for 20 MISFA with subsequent immediate implant placement. The patient population consisted of 11 women and 7 men aged 29-77 years (51 ± 16 years). In 2 subjects MISFA was performed bilaterally. A total of 5 patients suffered from 1 or 2 of the following diseases requiring permanent medication: hypertension (n = 4), cardiac arrhythmia (n = 1), hyperlipidemia (n = 1), restless legs syndrome (n = 1). All patients were non-smokers. Patients’ characteristics are summarized in Table I.

Sixty percent of the implants were placed in the position of the upper first molar and 40% were placed in the position of the upper second premolar (see Table II).

The residual bone height was 4.6 ± 1.4 mm. The thickness of the Schneiderian membrane was 1.6 ± 0.5 mm. The bone quality was as follows: type 2 in 1 case, between type 2 and 3 in 3 cases, and type 3 in the remaining 16 cases (see Table III).

Surgical procedure

All sinus lift procedures were performed by using the Jeder-System (Figure 1) which is fully CE-certified and distributed by Jeder GmbH, Vienna, Austria (www.jedersystem.com). The system consists of the Jeder-drill (Jeder GmbH, Vienna, Austria) (the actual surgical tool) (Figure 2), the Jeder-pump (Jeder GmbH, Vienna, Austria) (Figure 3), and a connecting tube-set. The pump generates high hydraulic pressure (1.5 bar) in the pressure-sealed system, thus pushing back the sinus membrane from the drill at the slightest perforation of the remaining bone. The pump also generates hydraulic vibrations to further raise and separate the membrane from the bone. The whole procedure is controlled by constantly measuring pressure and volume of the inserted fluid.

A surgical procedure using the Jeder-System consists of the following steps:

- Initially, a soft tissue punch (ATP-punch, DENTSPLY-Friadent, Mannheim, Germany) (Figure 4) is used at the implantation site without mucoperiosteal flap...
retraction. Then, the primary drill is taken until 1-2 mm below the sinus floor. To verify depth, an intraoperative radiograph can be done (Figure 5).

- Once the primary drilling has reached a sufficient depth shortly below the sinus floor, the Jeder-drill is plugged into the bore (pressure-sealed) (Figure 6) and high hydraulic pressure (1.5 bar) is built up in the pressure chamber of the Jeder-drill using physiological saline solution (NaCl). The centrally placed drill within the pressure chamber of the Jeder-drill slowly moves through the remaining crestal bone toward the sinus floor (Figure 7).

- Upon the first minimal perforation of the remaining bone, the pressurized fluid pushes back the membrane, ensuring that the drill does not perforate the membrane (Figure 8). At the same time, a sudden drop in pressure on the display of the Jeder-pump indicates the successful first entry into the sinus to the surgeon (Figure 9).

- After the perforation of the remaining bone, the saline solution — which is set into hydraulic vibrations (50 Hz) by the Jeder-pump — further separates the membrane from the bone. Thereby, space for the augmentation material and the implant is created. After extraction of the saline solution using the Jeder-pump the augmentation material and the implant are inserted (Figure 10).

- The whole procedure is constantly monitored by continuous measurement of the pressure and volume of the inserted fluid on the display of the Jeder-pump. The Jeder-pump features a built-in security mechanism to prevent introducing excessive pressure and fluid volume: As each step on the foot pedal of the Jeder-pump injects only 0.2 mL of saline solution, there is no danger for the Schneiderian membrane after the perforation of the bone (“high pressure, but very limited amount of liquid”). Additionally, all data are electronically recorded for documentation purposes.

A combination of Ostim (Heraeus Kulzer, Vienna, Austria) and Bio-Oss (Geistlich Biomaterials, Baden-Baden, Germany) was used as augmentation material. In total, 20 Ankylos screw type implants (DENTSPLY-Friadent, Mannheim, Germany) were placed immediately after MISFA. Implant diameters were 3.5 mm in

<table>
<thead>
<tr>
<th>Sinus lifts</th>
<th>Pre-operative residual bone height (mm)</th>
<th>Pre-operative sinus membrane thickness (mm)</th>
<th>Bone quality (Lekholm/Zarb index17)</th>
<th>Height gain (mm)</th>
<th>Total postoperative bone height (mm)</th>
<th>Implant length (mm)</th>
<th>Volume augmentation material (mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>7</td>
<td>1.5</td>
<td>3</td>
<td>6</td>
<td>13</td>
<td>11</td>
<td>0.70</td>
</tr>
<tr>
<td>2*</td>
<td>4</td>
<td>2</td>
<td>3</td>
<td>7</td>
<td>11</td>
<td>11</td>
<td>0.70</td>
</tr>
<tr>
<td>3*</td>
<td>4</td>
<td>1</td>
<td>3</td>
<td>11</td>
<td>15</td>
<td>11</td>
<td>0.70</td>
</tr>
<tr>
<td>4</td>
<td>4</td>
<td>2</td>
<td>3</td>
<td>10</td>
<td>14</td>
<td>11</td>
<td>0.85</td>
</tr>
<tr>
<td>5</td>
<td>3</td>
<td>1.5</td>
<td>3</td>
<td>11</td>
<td>14</td>
<td>11</td>
<td>0.75</td>
</tr>
<tr>
<td>6</td>
<td>3</td>
<td>1.5</td>
<td>3</td>
<td>6.5</td>
<td>9.5</td>
<td>9.5</td>
<td>0.60</td>
</tr>
<tr>
<td>7</td>
<td>4</td>
<td>2</td>
<td>3</td>
<td>7</td>
<td>11</td>
<td>11</td>
<td>0.95</td>
</tr>
<tr>
<td>8</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>8</td>
<td>11</td>
<td>11</td>
<td>0.80</td>
</tr>
<tr>
<td>9</td>
<td>4</td>
<td>2</td>
<td>2</td>
<td>9</td>
<td>13</td>
<td>11</td>
<td>0.85</td>
</tr>
<tr>
<td>10</td>
<td>4</td>
<td>2</td>
<td>3</td>
<td>11</td>
<td>15</td>
<td>11</td>
<td>0.95</td>
</tr>
<tr>
<td>11</td>
<td>4</td>
<td>1.5</td>
<td>3</td>
<td>9</td>
<td>13</td>
<td>11</td>
<td>0.85</td>
</tr>
<tr>
<td>12</td>
<td>5</td>
<td>2</td>
<td>3</td>
<td>10</td>
<td>15</td>
<td>11</td>
<td>0.95</td>
</tr>
<tr>
<td>13</td>
<td>7</td>
<td>1</td>
<td>2.5</td>
<td>10</td>
<td>17</td>
<td>11</td>
<td>1.00</td>
</tr>
<tr>
<td>14</td>
<td>4</td>
<td>1</td>
<td>3</td>
<td>11</td>
<td>15</td>
<td>11</td>
<td>0.85</td>
</tr>
<tr>
<td>15*</td>
<td>7</td>
<td>1.5</td>
<td>2.5</td>
<td>11</td>
<td>18</td>
<td>11</td>
<td>0.70</td>
</tr>
<tr>
<td>16*</td>
<td>4</td>
<td>1.5</td>
<td>2.5</td>
<td>8</td>
<td>12</td>
<td>11</td>
<td>0.70</td>
</tr>
<tr>
<td>17</td>
<td>4</td>
<td>1</td>
<td>3</td>
<td>9</td>
<td>13</td>
<td>11</td>
<td>1.05</td>
</tr>
<tr>
<td>18</td>
<td>4</td>
<td>1</td>
<td>3</td>
<td>9</td>
<td>13</td>
<td>11</td>
<td>0.85</td>
</tr>
<tr>
<td>19</td>
<td>7</td>
<td>2</td>
<td>3</td>
<td>10</td>
<td>17</td>
<td>14</td>
<td>0.75</td>
</tr>
<tr>
<td>20</td>
<td>6</td>
<td>1</td>
<td>3</td>
<td>11</td>
<td>17</td>
<td>11</td>
<td>0.75</td>
</tr>
</tbody>
</table>

Mean ± SD 4.6 ± 1.4 1.6 ± 0.5 2.9 ± 0.3 9.2 ± 1.7 13.8 ± 2.3 11.0 ± 0.7 0.8 ± 0.12

SD, standard deviation.

* Sinus lift performed bilaterally in 1 session.
4 cases and 4.5 mm in 16 cases. Implant length was 11 mm in all but 2 cases. One implant was 9.5 mm long while another one was 14 mm.

Peri- and postoperative care
Prior to surgery local anesthetic infiltration was administered buccally and palatally (articaine hydrochloride 4% with epinephrine 1:100,000 [Septanest with Epinephrine; Septodont, Niederkassel-Mondorf, Germany]). Postoperatively, patients were prescribed either clindamycin hydrochloride 300 mg (Clindac; Sandoz GmbH, Kundl, Austria) 3 times daily or josamycin 500 mg (Josalid; Sandoz) twice a day, for 1-week period. Following successful implantation the healing period until full implant load was 258 ± 81 days. Prosthetic rehabilitation included single crowns in 12 cases, implant bridge constructions in 6 cases (including 1 horseshoe implant bridge), and removable partial dentures in 2 patients.

Clinical and radiologic follow-up
On day 1 and day 3 after surgery, telephone follow-ups were conducted. One week postoperatively, every
patient completed a questionnaire including the degree of overall patient satisfaction — by use of a visual analog scale (VAS) (1 = not satisfied, 10 = very satisfied) — and including the days of sick leave. Between 4 and 6 weeks after surgery, a clinical examination and a control CT scan were performed aiming at detecting possible postoperative complications (e.g., sinusitis or sinus membrane perforation) as well as quantification of height gained by the augmentation procedure. All CT images were evaluated by 2 independent investigators not involved in the surgical procedures.

Eighteen months postoperatively (562 ± 34 days) implant stability was assessed in a clinical and radiologic [periapical radiograph and digital volume tomography (DVT)] examination. The survival criteria proposed by Buser et al. and Cochran et al. were followed at the 18-month control. They included the following: (1) absence of clinically detectable implant mobility, (2) absence of pain or any subjective sensation, (3) absence of recurrent peri-implant infection, and (4) absence of continuous radiolucency around the implant.

Statistical analysis
Descriptive statistical analysis including calculation of mean values and standard deviation (SD) of recorded data was carried out with Statistica software (release 6.0, StatSoft Inc., Tulsa, OK, USA). Data are presented as means ± SD.

RESULTS
In total, 20 MISFA were performed in 18 patients. Main data are summarized in Table III.

On the control CT scan performed 4-6 weeks postoperatively, a small amount of augmentation material was observed in a maxillary recessus in 1 out of 20 cases. Thus, the membrane perforation rate was 5%. The patient did not show any clinical symptoms and there was no implication for the implant placement. The respective patient is under close observation and at the 18-month follow-up there were no clinical symptoms related to this perforation of the Schneiderian membrane.

The control CT scan also showed that the residual bone height of 4.6 ± 1.4 mm could be augmented to 13.8 ± 2.3 mm corresponding to a height gain of 9.2 ± 1.7 mm.

Overall patient satisfaction with the surgical procedure was evaluated based on a questionnaire using a VAS ranging from 1 to 10 (1 = not satisfied, 10 = very satisfied). Average patient satisfaction was 9.82 ± 0.7 points. The mean duration of sick leave was 0.19 ± 0.5 days.
At the 18-month follow-up, none of the implants showed any mobility apart from 1 case where the implant was lost 9 months after surgery. Following insertion of a new implant at the same site 3 months after explantation, the new implant is still in place and functions well according to the patient’s feedback. The 18-month survival rate was therefore 95% (19 of 20 implants). None of the remaining implants showed any mobility, and there was no pain, redness, swelling, or suppuration at any implant site. None of the patients reported clinical symptoms of maxillary sinusitis, and also the DVT did not reveal any case of sinusitis.

**DISCUSSION**

The main finding of our study is that — within the limits of a prospective open cohort study with 20 cases — MISFA using the Jeder-System is a safe and effective method for cases with at least 3 mm residual alveolar ridge height.

**Height gain**

It is widely accepted in the literature that crestal methods currently in use are not predictable and reproducible if elevations >5 mm are needed. However, in the present study the height gain ranged from 6 to 11 mm (mean 9.2 ± 1.7 mm). In cadaveric studies it has been demonstrated that in a crestal approach the Schneiderian membrane can be lifted more than 10 mm without tearing. Membrane perforation can occur as soon as elevation forces exceed the load limits of the sinus membrane. As the Jeder-System uses hydraulic pressure, Pascal’s principle of even pressure distribution applies and allows optimized force transmission. Therefore, it can be concluded that the novel method can deliver a height gain that is comparable to the lateral approach.

**Perforation rate**

In the literature, perforation rates for indirect sinus floor augmentations usually vary between 0% and 44%. In reality, microscopic tears are, in many instances, impossible to diagnose and therefore their incidence frequency is often underestimated. Some authors explicitly state that small perforations (without clinical verification) might not have been detected, which means that the perforation rates reported in their studies would be too low.

In an endoscopically controlled osteotome sinus floor augmentation study, the validity of the Valsalva maneuver was questioned due to the limited
effectiveness to detect small perforations of the Schneiderian membrane.\textsuperscript{22} In our study, CT scans were undertaken before and 4-6 weeks after MISFA in all patients. Additionally, all CT images were evaluated by 2 independent investigators not involved in the surgical procedure. In one patient a small amount of augmentation material was radiologically visible in the upper recessus of the maxillary sinus without any clinical symptoms of sinusitis. Therefore, membrane perforation rate was considered to be 5% (1 of 20 cases). The perforation neither affected implant stability nor caused any problems for the patient. At the 18-month follow-up visit, the patient demonstrated no clinical symptoms or radiological signs of sinusitis and the implant loading was successful. We can confirm the finding\textsuperscript{9,22,28} that small membrane perforations are compatible with clinically healthy postoperative sinus conditions.

Survival rate

In his systematic review of 10 transcrestal sinus lift studies, Tan\textsuperscript{12} identified a reported mean implant success rate of 92.8%. This is almost the same as for implants placed in the posterior maxilla without grafting, i.e., 95.9%-97.7%.\textsuperscript{14,29} Watzek\textsuperscript{14} rightly remarks that the residual local bone height of 6-7 mm usually recommended for transcrestal sinus floor elevation means that implants of appropriate length should be firmly seated in the host bone. Therefore, at least in the first few years, Watzek considers it difficult to say whether implant stability was achieved because of transcrestal sinus floor elevation or on account of the bone volume-related short osseointegration segment sufficient for short implants.

For a residual bone height below the recommended range, the story is different. Without quantifying the effect, Tan\textsuperscript{12} confirms the finding of Rosen\textsuperscript{16} that the failure rate of the implants increased with and was correlated to reduced residual bone height. In a multicenter retrospective study, Rosen reported a survival rate of 96%, when the residual bone height was 5 mm or more, but the survival rate decreased to 85.7%, when the residual bone height was 4 mm or less. Watzek\textsuperscript{14} rightly remarks that at a residual bone height of <4 mm, implant survival has rarely been reported. In his own recent study with the gel-pressure technique, Watzek\textsuperscript{9} reports an implant survival rate 1 year after implant placement of 88.5% at sites with a pre-operative bone height of at least 4 mm (n = 26). This decreases to a 1 year survival rate of 50.0% for sites with a pre-operative bone height of <4 mm (n = 14).

In our study, the survival rate 18 months after implant placement was 94.1% at sites with a pre-operative bone height of at least 4 mm (n = 17) and 100% for sites with a pre-operative bone height of <4 mm (n = 3). Due to the small number of cases with residual bone height of <4 mm, further studies are needed to verify that the novel method can also yield high survival rates for sites with pre-operative bone height of <4 mm.

Side effects

All recorded side effects were considered slight or moderate. In particular, there were no signs of infection, sinusitis or nose bleeding after MISFA, while one hematoma was observed after local anesthesia. It could be shown that the novel method significantly reduces side effects compared to the considerably more invasive lateral approach. Thus, sick leave was very low in the present study at 0.17 ± 0.5 days compared to 4.5 ± 3.2 days after the lateral procedure (unpublished own data). Overall patient satisfaction was 9.87 ± 0.7 points on a VAS from 1 = not satisfied to 10 = very satisfied.

CONCLUSIONS

Within the limits of a prospective open cohort study with 20 cases, our data demonstrate the safety and medical efficacy of MISFA using the novel method. A height gain of 9.2 ± 1.7 mm could be achieved. In only one case a membrane perforation occurred without any clinical consequences. The 18-month survival rate was 95%. Side effects were acceptable and remarkably lower compared with the lateral approach. Sick leave occurrence was very low and overall patient satisfaction very high. To further evaluate the Jeder-System a broader clinical study (~ 100 cases) with international study centers is planned in the near future.

REFERENCES


Reprint requests:
Emanuel Bruckmoser, MD, DMD
Department of Oral and Maxillofacial Surgery
ABM University Health Board
Morriston Hospital
Swansea SA6 6NL, Wales, UK
emanuel.bruckmoser@wales.nhs.uk